Warning! GuruFocus detected
2 Medium warning signs
with ATB.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Antibiotice SA
ISIN : ROATBIACNOR9
Compare
Compare
Traded in other countries / regions
ATB.Romania0DMW.UK IPO Date
1997-04-16Description
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.24 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 0.87 | |||||
| Interest Coverage | 20.88 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.91 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.9 | |||||
| 3-Year EBITDA Growth Rate | 30.9 | |||||
| 3-Year EPS without NRI Growth Rate | 48.4 | |||||
| 3-Year FCF Growth Rate | -19.5 | |||||
| 3-Year Book Growth Rate | 13.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.97 | |||||
| 9-Day RSI | 25.48 | |||||
| 14-Day RSI | 29.54 | |||||
| 3-1 Month Momentum % | -6.56 | |||||
| 6-1 Month Momentum % | -27.98 | |||||
| 12-1 Month Momentum % | 41.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | |||||
| Quick Ratio | 1.48 | |||||
| Cash Ratio | 0.14 | |||||
| Days Inventory | 272.81 | |||||
| Days Sales Outstanding | 153.74 | |||||
| Days Payable | 129.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.75 | |||||
| Dividend Payout Ratio | 0.66 | |||||
| 3-Year Dividend Growth Rate | -35.6 | |||||
| Forward Dividend Yield % | 0.93 | |||||
| 5-Year Yield-on-Cost % | 0.68 | |||||
| Shareholder Yield % | 2.8 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.04 | |||||
| Operating Margin % | 14.17 | |||||
| Net Margin % | 14.34 | |||||
| FCF Margin % | 6.8 | |||||
| ROE % | 10.98 | |||||
| ROA % | 7.97 | |||||
| ROIC % | 8.85 | |||||
| 3-Year ROIIC % | 20.88 | |||||
| ROC (Joel Greenblatt) % | 10.58 | |||||
| ROCE % | 10.37 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.82 | |||||
| PE Ratio without NRI | 17.46 | |||||
| Shiller PE Ratio | 30.49 | |||||
| Price-to-Owner-Earnings | 16.57 | |||||
| PEG Ratio | 1.13 | |||||
| PS Ratio | 2.3 | |||||
| PB Ratio | 1.68 | |||||
| Price-to-Tangible-Book | 1.77 | |||||
| Price-to-Free-Cash-Flow | 33.33 | |||||
| Price-to-Operating-Cash-Flow | 10.48 | |||||
| EV-to-EBIT | 15.79 | |||||
| EV-to-EBITDA | 11.23 | |||||
| EV-to-Revenue | 2.44 | |||||
| EV-to-FCF | 37.73 | |||||
| Price-to-GF-Value | 2.08 | |||||
| Price-to-Projected-FCF | 1.44 | |||||
| Price-to-Median-PS-Value | 2.24 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.7 | |||||
| Price-to-Graham-Number | 1.18 | |||||
| Price-to-Net-Current-Asset-Value | 14.67 | |||||
| Earnings Yield (Greenblatt) % | 6.33 | |||||
| FCF Yield % | 2.97 | |||||
| Forward Rate of Return (Yacktman) % | 21.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Antibiotice SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil lei) | 643.401 | ||
| EPS (TTM) (lei) | 0.139 | ||
| Beta | 1.39 | ||
| 3-Year Sharpe Ratio | 1.23 | ||
| 3-Year Sortino Ratio | 3.98 | ||
| Volatility % | 51.37 | ||
| 14-Day RSI | 29.54 | ||
| 14-Day ATR (lei) | 0.057822 | ||
| 20-Day SMA (lei) | 2.3365 | ||
| 12-1 Month Momentum % | 41.52 | ||
| 52-Week Range (lei) | 1.69 - 3.44 | ||
| Shares Outstanding (Mil) | 671.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Antibiotice SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Antibiotice SA Stock Events
| Event | Date | Price (lei) | ||
|---|---|---|---|---|
| No Event Data | ||||
Antibiotice SA Frequently Asked Questions
What is Antibiotice SA(BSE:ATB)'s stock price today?
The current price of BSE:ATB is lei2.20. The 52 week high of BSE:ATB is lei3.44 and 52 week low is lei1.69.
When is next earnings date of Antibiotice SA(BSE:ATB)?
The next earnings date of Antibiotice SA(BSE:ATB) is .
Does Antibiotice SA(BSE:ATB) pay dividends? If so, how much?
The Dividend Yield %  of Antibiotice SA(BSE:ATB) is 3.75% (As of Today), Highest Dividend Payout Ratio of Antibiotice SA(BSE:ATB) was 4.5. The lowest was 0.04. And the median was 0.51. The  Forward Dividend Yield % of Antibiotice SA(BSE:ATB) is 0.93%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers